TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
non-small cell lung cancer
Advertisement
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Leads Biolabs’ Opamtistomig Shows Strong NSCLC Response Ahead of WCLC 2026
NANJING, China, May 28, 2026 Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB...
Ellipses Pharma and Kelun-Biotech Present EP0031 Data at ASCO 2026
LONDON, May 22, 2026 Ellipses Pharma and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that pivotal Phase 2 clinical trial...
Innovent’s IBI363 Shows Strong First-Line NSCLC Data
SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...
Advertisements
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
A2 Bio Reports First CAR-T Complete Response in Lung Cancer
CHICAGO, Illinois, 21 May 2026 A2 Biotherapeutics, Inc. announced new safety and efficacy results from its ongoing EVEREST-2 Phase...
Bayer’s Asundexian Wins FDA Priority Review
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
MEKanistic Clears FDA IND for MTX-531 Cancer Trial
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
Advertisement
